Acorda Therapeutics (ACOR) was turned away at the FDA’s doorstep when it tried to submit a marketing application for a new drug to treat Parkinson’s disease. The embarrassing regulatory miscue disclosed Tuesday will delay the drug’s approval.

Shares of Acorda fell 27 percent to $18.75 in Tuesday pre-market trading.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.